• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » T2 Biosystems wins CE Mark for MR-based bacteria detector, closing in on FDA bid

T2 Biosystems wins CE Mark for MR-based bacteria detector, closing in on FDA bid

July 18, 2017 By Fink Densford

T2 Biosystems

T2 Biosystems Inc. (NSDQ:TTOO) said today it won CE Mark approval in the European Union for its T2Bacteria Panel magnetic resonance-based bacterial detector, and said that it has entered the final stages of its FDA pivotal trial as it seeks 510(k) approval from the agency.

The T2Bacteria Panel is designed to run on the company’s T2Dx instrument, a miniaturized MR diagnostic device, to provide species-specific test results of targeted bacterial infections in approximately 3.5 hours, the Lexington, Mass.-based company said.

The T2Bacteria Panel is designed to identify 6 of the deadliest prevalent bacteria species not covered by empiric therapy. The company said the system can identify approximately 90% of gram-negative infections coming in through ER departments and 70% of community-acquired infections in emergency departments.

The device is slated for a commercial launch as part of its T2Sepsis Solution in Europe during the 3rd quarter of this year, T2 Biosystems said.

“The CE Mark of our T2Bacteria Panel is a significant milestone in our mission to save lives and improve healthcare by empowering clinicians to more effectively treat patients with sepsis faster than ever before. Our T2Sepsis Solution now includes T2Candida and T2Bacteria, creating a significant opportunity to expand our target hospitals and positioning T2 Biosystems for accelerated commercial growth,” prez & CEO John McDonough said in a press release.

The company said that patient enrollment in its pivotal FDA trial of the T2Bacteria Panel is at 92%, and that initial results from the trial show an average sensitivity of 96% and average specificity of 98%.

“We are pleased to be close to finalizing the submission of our T2Bacteria Panel to the FDA. Even more encouraging are the early responses we have been receiving from hospitals taking advantage of the T2Bacteria Panel under the RUO program.  We believe the RUO program will provide independent data for hospitals to present at conferences and for publications later this year and into 2018,” chief scientific officer Tom Lowery said in a prepared statement.

Last month, T2 Biosystems touted data showing that its miniaturized magnetic resonance diagnostic tech can detect Lyme disease-causing bacteria in clinical blood samples. The preclinical study was published in the Journal of Clinical Microbiology. 

Filed Under: Diagnostics, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: T2 Biosystems Inc.

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy